The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Role of Biomarkers in Patients with Breast Cancer

Susan M. Domchek, MD
Published Online:5:37 PM, Thu March 8, 2018

Susan M. Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.

Additionally, she notes, mutations such as BRCA-1 and BRCA-2 can be identified and would require different treatment plans.

Domchek notes that pembrolizumab (Keytruda) has been approved by the FDA when a tumor displays high microsatellite instability. Though this tends to be uncommon, it shows that there are a variety of agents that can be used based on different biomarkers.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.